1. Home
  2. PSA vs NTRA Comparison

PSA vs NTRA Comparison

Compare PSA & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PSA

Public Storage

SELL

Current Price

$330.17

Market Cap

55.2B

Sector

Real Estate

ML Signal

SELL

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$287.44

Market Cap

56.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSA
NTRA
Founded
1972
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.2B
56.7B
IPO Year
2007
2015

Fundamental Metrics

Financial Performance
Metric
PSA
NTRA
Price
$330.17
$287.44
Analyst Decision
Hold
Strong Buy
Analyst Count
22
22
Target Price
$343.39
★ $410.26
AVG Volume (30 Days)
990.2K
★ 1.9M
Earning Date
10-26-2026
11-05-2026
Dividend Yield
★ 3.60%
N/A
EPS Growth
N/A
★ 0.65
EPS
★ 6.92
N/A
Revenue
★ $4,824,113,000.00
$210,939,000.00
Revenue This Year
$7.25
$30.65
Revenue Next Year
$7.82
$21.31
P/E Ratio
$48.23
★ N/A
Revenue Growth
★ 2.74
N/A
52 Week Low
$256.54
$181.00
52 Week High
$345.89
$437.41

Technical Indicators

Market Signals
Indicator
PSA
NTRA
Relative Strength Index (RSI) 62.81 26.33
Support Level $308.79 $189.54
Resistance Level $345.89 $288.04
Average True Range (ATR) 6.17 21.43
MACD -0.63 -10.31
Stochastic Oscillator 56.24 5.81

Price Performance

Historical Comparison
PSA
NTRA

About PSA Public Storage

Public Storage is the largest owner of self-storage facilities in the US, with more than 3,500 self-storage facilities in 40 states and approximately 259 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage. The company also has a merchandise business, a third-party property management business, and an insurance business that offers products to cover losses for the goods in self-storage facilities.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: